SecBot SecBot
PRESS-RELEASE ·Filed Apr 10, 2026

MESO

Mesoblast Limited
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This direct path to a registrational trial without a required Phase 2 is highly unusual and de-risks development. Traders should monitor trial initiation and patient enrollment trends; success could position Ryoncil® as a first-in-class anti-inflammatory therapy for DMD, significantly expanding its market potential beyond SR-aGvHD.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.70
T+0 close · Apr 10, 2026 · via day close
Latest settled
+0.68%
T+60 · $14.80
Vs SPY
−8.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $14.70entry
  2. T+1 · 7mo ago −0.61%α −1.82% · $14.61
  3. T+5 · 7mo ago +12.99%α +9.70% · $16.61
  4. T+20 · 6mo ago −1.29%α −9.02% · $14.51
  5. T+60 · 4mo ago +0.68%α −8.24% · $14.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast received FDA clearance to proceed directly into a registrational trial for Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), a rare and fatal muscle-wasting disease affecting ~15,000 children in the U.S. The Phase 3 trial will enroll 76 patients aged 5–9, with primary endpoint of time-to-stand at nine months.

Key Facts

  • FDA granted IND clearance for a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD).
  • Trial will enroll 76 pediatric patients (ages 5–9), randomized to Ryoncil® or placebo, with time-to-stand at 9 months as the primary endpoint.
  • Ryoncil® is already FDA-approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, supporting its safety profile.
  • Mesoblast is partnering with Parent Project Muscular Dystrophy (PPMD) and the Duchenne Registry for patient identification and trial awareness.

Financial Impact

Potential blockbuster expansion into a new pediatric indication with no approved disease-modifying therapies targeting inflammation in DMD.

revenuemarketCapvaluation

Risk Factors

  • Clinical failure in the registrational trial despite strong preclinical data.
  • Limited sample size (76 patients) may raise concerns about statistical power.
  • Competition from gene therapies and exon-skipping drugs targeting dystrophin restoration.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272039

Track record

25 reports on MESO

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026